Nektar Therap Trials - LARVOL Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Exubera (recombinant human insulin inhalational) / Nektar Therap

NCT01798914: Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder

No Longer Available

N/A

Technosphere Insulin Inhalation Powder, Afrezza Inhalation Powder

Mannkind Corporation

Type 1 Diabetes, Type 2 Diabetes

04/15

05/15

dapirolizumab pegol (CDP7657) / Biogen, UCB, Nektar Therap

2019-003407-35: A Study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with moderately to severely active systemic lupus erythematosus Estudio para evaluar la eficacia y la seguridad del dapirolizumab pegol en participantes en el estudio con lupus eritematoso sistémico de moderado a grave

Ongoing

450

Europe

Dapirolizumab pegol, CDP7657, Powder for solution for infusion

UCB Biopharma SRL, UCB Biopharma SRL

Systemic lupus erythematosus (SLE) Lupus eritematoso sistémico (SLE), Systemic lupus erythematosus is a chronic autoimmune inflammatory disease which can present with a persistent active disease coursebut has more often a relapsing-remitting disease course El lupus eritematoso sistémico es una enfermedad inflamatoria crónica de carácter autoinmunitario que, aunque puede presentar un curso crónico, por lo común presenta un curso recidivante-remitente., Body processes [G] - Immune system processes [G12]

PHOENYCS GO, NCT04294667 / 2019-003406-27: A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Jan 2024 - Jun 2024 : Topline data for SLE

Completed

321

Europe, Canada, US, RoW

DZP, CDP7657, Placebo, PBO

UCB Biopharma SRL

Systemic Lupus Erythematosus

05/24

06/24

PHOENYCS FLY, NCT06617325: A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Not yet recruiting

450

DZP, CDP7657, Placebo, PBO

UCB Biopharma SRL

Systemic Lupus Erythematosus

03/27

NCT04976322 / 2019-003409-83: A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

Enrolling by invitation

760

Europe, Canada, US, RoW

Dapirolizumab pegol, DZP, CDP7657

UCB Biopharma SRL, UCB Biopharma SRL

Systemic Lupus Erythematosus

04/29

2019-001967-58: Efficacy and Safety Study of Dapirolizumab pegol (BIIB133) in Participants with Relapsing Multiple Sclerosis (RMS)

Not yet recruiting

220

Europe

Dapirolizumab Pegol, OCREVUS, BIIB133, Lyophilisate for solution for infusion, Concentrate for solution for infusion, Ocrevus

Biogen Idec Research Limited, Biogen Idec Research Limited

Relapsing Multiple Sclerosis, Relapsing Multiple Sclerosis, Diseases [C] - Nervous System Diseases [C10]

pegvorhyaluronidase alfa (PEGPH20) / Halozyme

NCT01959139: S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

Completed

1/2

126

PEGPH20, Pegylated Recombinant Human Hyaluronidase, Oxaliplatin, Eloxatin, NSC-266046, Leucovorin, leucovorin calcium, Irinotecan, CPT-11, NSC-616348, 5-fluorouracil, 5-FU, Adrucil, NSC-19893

SWOG Cancer Research Network, National Cancer Institute (NCI), Halozyme Therapeutics

Metastatic Pancreatic Adenocarcinoma

04/19

11/23

MORPHEUS-EC, NCT03281369 / 2016-004529-17: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Active, not recruiting

1/2

410

Europe, US, RoW

5-Fluorouracil (5-FU), Leucovorin, Folinic acid, Oxaliplatin, Atezolizumab, Tecentriq, Cobimetinib, Cotellic, Ramucirumab, Paclitaxel, PEGylated recombinant human hyaluronidase (PEGPH20), BL-8040, Linagliptin, Cisplatin, Tiragolumab, RO7092284

Hoffmann-La Roche, Halozyme Therapeutics, BioLineRx, Ltd.

Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

04/25

MORPHEUS-PDAC, NCT03193190 / 2016-004126-42: A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

	Feb 2024 - Jun 2024 : Results from MORPHEUS-PDAC trial in 1L mPDAC
	In combination with BL-8040 for pancreatic ductal adenocarcinoma
	Dec 2019 - Dec 2019: In combination with BL-8040 for pancreatic ductal adenocarcinoma

Active, not recruiting

1/2

340

Europe, Japan, US, RoW

Nab-Paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Fluorouracil, Atezolizumab, Cobimetinib, PEGPH20, BL-8040, Selicrelumab, Bevacizumab, RO6874281, AB928, Tiragolumab, Tocilizumab

Hoffmann-La Roche

Pancreatic Adenocarcinoma

01/25

NCT02921022: Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

Active, not recruiting

N/A

110

Gemcitabine, Nab-paclitaxel, PEGPH20

Memorial Sloan Kettering Cancer Center, Halozyme Therapeutics, Miami Cancer Institute

Pancreatic Cancer, Advanced Pancreatic Ductal Adenocarcinoma

10/25

Adynovate (rurioctocog alfa pegol) / Takeda

NCT04784988: Intensive Replacement Treatment in Haemophilia Patients With Synovitis

Completed

Europe

EHL-FVIII, FVIII concentrate

Federico II University

Hemophilia A

03/23

03/24

NCT04690322: POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies

Recruiting

Eloctate, ELOCTATE- antihemophilic factor (recombinant), fc fusion protein, Adynovate, ADYNOVATE- antihemophilic factor (recombinant) pegylated, Emicizumab, HEMLIBRA- emicizumab injection, solution

University of Texas Southwestern Medical Center

Hemophilia A, Factor VIII

07/25

NCT02615691 / 2015-002136-40: A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A

Completed

120

Europe, Canada, US, RoW

PEGylated Recombinant Factor VIII, ADYNOVATE, BAX 855, TAK-660, ITI

Baxalta now part of Shire, Takeda Development Center Americas, Inc.

Hemophilia A

10/24

NCT05707351: A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A

Completed

RoW

Adynovate, Antihemophilic Factor (recombinant) PEGylated, Rurioctocog Alfa Pegol

Takeda

Hemophilia A

09/24

NCT04876365: A Study in Children, Teenagers and Adults With Severe Hemophilia A Who Switched From Other Factor VIII Treatments to Adynovate

Completed

N/A

153

Canada

Non-Interventional

Takeda

Hemophilia A

02/22

NCT03006965: Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT®

Completed

N/A

Europe

octocog alfa, Advate®, recombinant intravenous factor VIII, rurioctocog alfa pegol

Spanish Society of Thrombosis and Haemostasis, Takeda, Instituto de Investigación Hospital Universitario La Paz

Hemophilia A, Hemophilia, Factor VIII Deficiency

12/22

NCT03169972: ADYNOVATE Drug Use-Results Survey

Completed

N/A

135

Japan

ADYNOVATE, BAX 855, BAX855, Recombinant Factor VIII (FVIII) PEGylated

Takeda, Takeda

Hemophilia A

09/23

NCT04941898: A Study of TAK-660 in Surgical Procedures for People With Hemophilia A.

Completed

N/A

Japan

PEGylated Recombinant Factor VIII, TAK-660, BAX855, ADYNOVATE

Takeda

Hemophilia A

03/24

AHEAD, NCT02078427: ADVATE/ ADYNOVI Hemophilia A Outcome Database


	Jul 2016 - Jul 2016:

	Jul 2016 - Jul 2016:

	Jan 2015 - Jan 2015:
More

Completed

N/A

951

Europe, Canada, RoW

ADVATE, octocog alfa, rAHF-PFM, ADYNOVI, rurioctocog alfa pegol, rAHF-PEG

Baxalta now part of Shire, Baxalta Innovations GmbH, now part of Shire

Hemophilia A

01/24

NCT03824522: Post Marketing Surveillance Study for ADYNOVATE in South Korea

Completed

N/A

341

RoW

ADYNOVATE, PEGylated rFVIII

Takeda, Takeda Pharma Korea Co. Ltd.

Hemophilia A

01/24

NCT04158934: A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

Active, not recruiting

N/A

207

Europe, US, RoW

ADYNOVI/ADYNOVATE, Antihaemophilic Factor [Recombinant] PEGylated rurioctocog alfa pegol, TAK-660, BAX 855

Baxalta now part of Shire

Hemophilia A

02/30

Onzeald (etirinotecan pegol) / Nektar Therap

2008-005578-12: A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic or Locally Advanced Cervical Cancer

Ongoing

Europe

PEG-Irinotecan, NKTR-102,

Nektar Therapeutics

Patients with Metastatic or Locally Advanced Cervical Cancer

NCT05158491: Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC

Recruiting

1/2

RoW

JK-1201I, PEG-Irinotecan

JenKem Technology Co., Ltd., Beijing Cancer Hospital

Small Cell Lung Cancer (SCLC)

12/22

03/23

Movantik (naloxegol) / AstraZeneca, RedHill, Kyowa Kirin

2018-000013-20: Study in which the effects of codein and Naloxegol (antidote) on colonic motoric contractions are evaluated Studie waarbij het effect van codeine en Naloxegol (tegenwerkend middel) op de contracties van dikke darm worden geëvalueerd

Ongoing

Europe

Moventig, Bronchodine, Bisacodyl, Tablet, Syrup, Moventig, Bronchodine, Bisacodyl

KU Leuven, KU Leuven

This study will be performed in healthy volunteers. Dit onderzoek zal worden uitgevoerd in gezonde vrijwilligers., This study will be performed in healthy volunteers. Dit onderzoek zal worden uitgevoerd in gezonde vrijwilligers., Body processes [G] - Physiological processes [G07]

NaloxegolHRM, NCT05770960: Colonic Motor Patterns in Healthy Volunteers

Completed

Europe

Naloxegol, Movantik, Moventig, codeine phosphate, Bronchodine, Placebo, Siripus simplex syrup

Universitaire Ziekenhuizen KU Leuven

Opioid-Induced Constipation

05/19

NCT03235739: Ancillary Effects of Oral Naloxegol (Movantik)

Completed

136

Naloxegol 25 MG, Movantik, Placebo

The Cleveland Clinic

Pain, Postoperative

05/21

05/22

NCT03523520: Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation

Completed

Methylnaltrexone Bromide 150 mg Oral Tablet, Relistor, Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1, Naloxegol 25 MG Oral Tablet, Movantik

University of Missouri-Columbia

Constipation Drug Induced

03/23

2020-000087-26: Time to transit Recovery After treatment with Naloxegol in cardiac Surgery Intensive care Trial Intérêt du Naloxégol dans la reprise du transit en postopératoire de chirurgie cardiaque

Not yet recruiting

300

Europe

Tablet, MOVENTIG 12.5 mg et 25 mg

CMC AMBROISE PARE, CMC Ambroise Paré

ileus after cardiac surgery iléus post chirurgie cardiaque, constipation induised by opioïdes after cardiac surgery constipation induite par les opioïdes en poste chirurgie cardiaque, Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]

2019-000959-14: The NIPA study: A randomized double-blind control clinical trial Naloxegol administration to prevent opioids induced gastrointestinal motility disturbance in brain Injured PAtients. Etude NIPA : Essai contrôlé randomisé en double aveugle évaluant l’administration prophylactique de Naloxegol pour prévenir les troubles de la motilité gastro-intestinale induits par les opioïdes chez les patients cérébrolésés.

Not yet recruiting

370

Europe

MOVENTIG® (Naloxégol) 25 mg, Tablet, MOVENTIG® (Naloxégol) 25 mg

CHRU de Brest, Health Ministry

Prevent opioids induced gastrointestinal motility disturbance in brain Injured Patients. Prévention des troubles de la motilité gastro-intestinale induits par les opioïdes chez les patients cérébrolésés., Brain injured patients. Patients cérébrolésés., Diseases [C] - Digestive System Diseases [C06]

NIPA, NCT05008926: The Study Naloxegol Administration to Prevent Opioids Induced Gastrointestinal Motility Disturbance in Brain Injured PAtients

Recruiting

370

Europe

Naloxegol, Placebo

University Hospital, Brest

Brain Injuries

03/26

09/26

NCT03316859: Naloxegol and Opioid-induced Constipation

Recruiting

2/3

280

Naloxegol 25 MG, Movantik, Placebo pill

TriHealth Inc.

Constipation, Constipation Drug Induced

12/22

2015-000419-42: Naloxegol and assessments of opioid induced bowel dysfunction

Ongoing

Europe

Moventig, OxyContin, Film-coated tablet, Prolonged-release tablet, Moventig, OxyContin

Aalborg University Hospital, Astra Zeneca

Healthy volunteers (Opioid-induced bowel dysfunction), Healthy volunteers (Adverse effects of opioids on the gut), Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]

NCT03087708: Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Terminated

Naloxegol, Placebo, Laboratory Biomarker Analysis, Quality-of-Life Assessment

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)

Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer

01/21

04/23

2020-003687-10: To evaluate in patients with opioid induced constipation if the use of Naloxegol may improve gastric emptying rate and gastric symptoms

Not yet recruiting

Europe

Moventig, Tablet, Moventig

UZLeuven, Kyowa Kirin Holdings BV

Opioid induced gastrointestinal dysfunction, gastrointestinal symptoms caused by opioid intake, Diseases [C] - Digestive System Diseases [C06]

ANTAGOCYST-01, NCT04219046: Evaluation of Naloxegol in the Prevention of POI After Cystectomy

Not yet recruiting

102

Naloxégol oxalate, Naloxegol, Placebo oral tablet, Placebo

Institut Paoli-Calmettes

Bladder Cancer, Cystostomy; Complications

09/22

12/22

NCT02813369: Naloxegol Health Outcome Post Authorisation Safety Study

Terminated

N/A

10000

Europe

naloxegol, non-PAMORA laxative

Kyowa Kirin Pharmaceutical Development Ltd

Opioid Induced Constipation

11/21

NCT02813356: Naloxegol US PMR CV Safety.

Active, not recruiting

N/A

8800

naloxegol, non-PAMORA

Valinor Pharma LLC

Opioid Induced Constipation

12/23

NCT03720613: Risk of Major Adverse Cardiovascular Events for Naldemedine and Other Medications for Opioid Induced Constipation in Adults With Chronic Non-Cancer Pain

Recruiting

N/A

34532

Naldemedine, Symproic®, Lubiprostone, Amitiza®, Naloxegol, Movantik®

BioDelivery Sciences International, HealthCore, Inc.

Opioid-induced Constipation

11/30

bempegaldesleukin (NKTR-214) / Nektar Therap, BMS, Ono Pharma

PIVOT IO 001, NCT03635983 / 2018-001423-40: A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

	Data from trial in combination with Opdivo for 1L metastatic melanoma
	Mar 2022 - Mar 2022: Data from trial in combination with Opdivo for 1L metastatic melanoma

Completed

783

Europe, Canada, US, RoW

NKTR-214, Bempegaldesleukin, BMS-986321, Nivolumab, Opdivo, BMS-936558

Bristol-Myers Squibb, Nektar Therapeutics

Melanoma

11/21

03/24

CA045-009, NCT04209114 / 2018-002676-40: A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Jan 2023 - Dec 2024: From trial in combination with nivolumab for first-line muscle-invasive bladder cancer

Completed

114

Europe, Canada, US, RoW

Nivolumab, Opdivo, BMS-936558, Radical cystectomy (RC), Bempegaldesleukin, BMS-986321, NKTR-214, Bempeg

Bristol-Myers Squibb, Nektar Therapeutics

Bladder Cancer, Bladder Tumor, Muscle-Invasive Bladder Cancer

06/23

NCT04936841: Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma

Terminated

NKTR-214, bempegaldesleukin, anti-PD-1 therapy, Pembrolizumab, Palliative Radiation

University of Wisconsin, Madison, Nektar Therapeutics

Head and Neck Cancer

10/22

NCT03282344: A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Active, not recruiting

NKTR-214, Nivolumab

Memorial Sloan Kettering Cancer Center, M.D. Anderson Cancer Center, Stanford University, Rockefeller University

SARCOMA

09/25

2018-003200-39: A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined with Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI alone in Participants with Previously Untreated Kidney Cancer That is Advanced or has Spread Estudio para comparar bempegaldesleukin (BEMPEG: NKTR-214) combinado con nivolumab y un inhibidor de la tirosina quinasa (TKI) con nivolumab y un TKI solos en participantes con cáncer de riñón no tratado previamente que ha avanzado o se ha extendido

Not yet recruiting

1/2

298

Europe

NIVOLUMAB - 10ml vial - COMMERCIAL, Cabozantinib, BMS-936558, NKTR-214 - 1 mg vial, XL184, Concentrate and solvent for concentrate for solution for infusion, Powder for solution for infusion, Film-coated tablet, Opdivo (100 mg/10 ml), CABOMETYX

Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb International Corporation

Renal Cell Carcinoma Carcinoma de células renales, Kidney cancer Cáncer de riñón, Diseases [C] - Cancer [C04]

2019-003474-35: A study to investigate the use of the study drug Combined Bempegaldesleukin (NKTR-214) and Pembrolizumab with or without Chemotherapy for solid tumours.

Not yet recruiting

1/2

400

Europe

bempegaldesleukin, Pembrolizumab, Paclitaxel, Nab-paclitaxel, Cisplatin, Carboplatin, Pemetrexed, CISPLATIN, NKTR-214, L01CD01, Lyophilisate for solution for injection, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Powder for suspension for injection, Powder for dispersion for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion., Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Abraxane, CISPLATINUM (CISPLATIN), CARBOPLATIN, PEMETREXED, BENDATAX (PACLITAXEL), ABRAXANE (PACLITAXEL FORMULATED AS ALBUMIN BOUND NANOPARTICLES), CISPLATIN Neocorp, CISPLATIN, CARBOPLATIN (Ribocarbo), CARBOPLATIN (CARBO-CELL), PACLITAXEL

Nektar Therapeutics, NEKTAR THERAPEUTICS, Nektar Therapeutics

Patients with with locally advanced or metastatic solid tumors., Patients with a solid tumor cancer that has grown or spread, Diseases [C] - Cancer [C04]

DIRECT-01, NCT03548467: A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer

Completed

1/2

Europe

VB10.NEO, Bempegaldesleukin, NKTR-214

Nykode Therapeutics ASA, Nektar Therapeutics, Vaccibody AS

Locally Advanced or Metastatic Solid Tumours

01/23

PIVOT IO 011, NCT04540705: A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread

Completed

Europe, Canada, US, RoW

Nivolumab, OPDIVO, Axitinib, INLYTA, Cabozantinib, Cabometyx

Bristol-Myers Squibb, Nektar Therapeutics

Renal Cell Carcinoma

01/24

avipendekin pegol (NKTR-255) / Nektar Therap

NCT05664217: NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

Recruiting

2/3

400

NKTR-255 at 1.5 µg/kg, Polymer-conjugated interleukin (IL)-15 Receptor Agonist, NKTR-255 at 3.0 μg/kg, NKTR-255 at 3.0/6.0 μg/kg, Placebo Comparator

Nektar Therapeutics

Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma

01/27

01/29

2021-003669-36: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Not yet recruiting

280

Europe

BAVENCIO, sacituzumab govitecan, MSB0010718C, IMMU-132, M6223, NKTR-255, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, BAVENCIO, Trodelvy

Merck Healthcare KGaA, MERCK KGAA, Merck Healthcare KGaA

Advanced or metastatic urothelial carcinoma whose disease did not progress with 1L platinum-containing chemotherapy., Bladder cancer, Diseases [C] - Cancer [C04]

JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting

256

Europe, Canada, US, RoW

Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics

Locally Advanced or Metastatic Urothelial Carcinoma

01/25

RESCUE, NCT05632809: REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors

Recruiting

NKTR-255, Durvalumab

M.D. Anderson Cancer Center, Nektar Therapeutics

Lung Cancer

12/25

12/27

2021-002177-25: A study on NKTR-255 in combination with Cetuximab as salvage treatment for Solid Tumors Estudio sobre NKTR-255 en combinación con Cetuximab como tratamiento de rescate para tumores sólidos.

Not yet recruiting

1/2

Europe

NKTR-255, cetuximab, NKTR-255, Lyophilisate for solution for infusion, Solution for infusion, Erbitux

Nektar Therapeutics, NEKTAR THERAPEUTICS, Nektar Therapeutics

Relapsed or refractory (R/R) head and neck squamous cell carcinoma (HNSCC) or colorectal carcinoma (CRC) Carcinoma escamoso de cabeza y cuello (CECC) o carcinoma colorrectal (CCR) recidivante o resistente (R/R), Head and neck squamous cell cancer or colorectal cancer which has spread to other part of body Cáncer epidermoide de cabeza y cuello o cáncer colorrectal que se ha extendido a otra parte del cuerpo, Diseases [C] - Cancer [C04]

NCT04616196: Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

Completed

1/2

NKTR-255, Cetuximab, Erbitux®

Nektar Therapeutics

Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Cervical Cancer

03/23

NCT04136756: NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma

Completed

NKTR-255, NKTR-255 Q21, Rituximab, RITUXAN(R), Daratumumab, DARZALEX FASPRO(TM)

Nektar Therapeutics

Multiple Myeloma, Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma

04/23

NCI-2022-02316, NCT05359211: NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Recruiting

Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Asta B 518, B-518, Fludarabine, Fluradosa, Lisocabtagene Maraleucel, Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes JCAR017, Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes JCAR017, Autologous Anti-CD19-EGFRt-4-1BB-zeta-modified CAR CD8+ and CD4+ T-lymphocytes JCAR017, Breyanzi, JCAR 017, JCAR017, Liso-cel, Polymer-conjugated IL-15 Receptor Agonist NKTR-255, IL-15 Receptor Agonist NKTR-255, Long-acting Polymer-conjugated IL-15, NKTR 255, NKTR-255, NKTR255, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, Plain film radiographs, Radiographic Imaging, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Synchronized Multigated Acquisition Scanning, RNVG, SYMA Scanning, Bone Marrow Biopsy, Biopsy of Bone Marrow, Bone Marrow Aspiration, Lumbar Puncture, LP, spinal tap, Computed Tomography, CAT Scan, Computed Axial Tomography, CT, CT SCAN, Positron Emission Tomography, PET, PET scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Biospecimen Collection, Biological Sample Collection, Biopsy, Bx

Fred Hutchinson Cancer Center, Nektar Therapeutics

Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory Primary Mediastinal Large B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

12/24

12/25

IRB-41382, NCT03233854: CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

Active, not recruiting

Chimeric Antigen Receptor T-Cell Therapy, CAR T-cell therapy, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, Questionnaire Administration, NKTR-255

Crystal Mackall, MD, California Institute for Regenerative Medicine (CIRM)

B Acute Lymphoblastic Leukemia, CD19 Positive, Minimal Residual Disease, Philadelphia Chromosome Positive

09/25

09/35

NCT05676749: C-TIL051 in Non-Small Cell Lung Cancer

Recruiting

C-TIL051, Pembrolizumab, NKTR-255

AbelZeta, Inc., Nektar Therapeutics

Metastatic Non Small Cell Lung Cancer

03/26

08/27

rezpegaldesleukin (NKTR-358) / Nektar Therap

ISLAND-SLE, NCT04433585 / 2019-003323-38: A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)

Completed

291

Europe, Canada, Japan, US, RoW

LY3471851, Rezpegaldesleukin, REZPEG, NKTR-358, Placebo

Nektar Therapeutics, Eli Lilly and Company

Systemic Lupus Erythematosus

01/23

02/23

REZOLVE-AD, NCT06136741: A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

Recruiting

396

Europe, Canada, US, RoW

Rezpegaldesleukin, NKTR-358, REZPEG, LY3471851 (formerly), Placebo

Nektar Therapeutics

Moderate to Severe Atopic Dermatitis

05/25

12/25

NCT06340360: A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

Recruiting

Canada, US

Rezpegaldesleukin, REZPEG, NKTR-358, LY3471851 (formerly), Placebo

Nektar Therapeutics

Alopecia Areata

08/25

08/26

NCT05565729: A Phase I Study of LY3471851 in Healthy Participants

Completed

LY3471851, NKTR-358, Placebo, Levocetirizine

Nektar Therapeutics, Eli Lilly and Company

Healthy

02/23

NKTR-262 / Nektar Therap

No trials found

NKTR-288 / Nektar Therap

No trials found



	Diseases Companies Products Productz Mechanisms of Action Sites